Clinical trial
Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell…
NCT00169169 · Lymphoma Study Association, Other · Terminated
Key facts
| NCT number | NCT00169169 |
|---|---|
| Title | Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma |
| Official title | Randomised Phase 3 Study of Rituximab in High-Risk Patients With Diffuse Large B-Cell Lymphoma Who Received a First-Line Consolidative Chemotherapy With Autologous Stem Cell Transplant (ASCT). |
| Lead sponsor | Lymphoma Study Association, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | CD20-Positive Large B-Cell Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | ACVBP, ACE, rituximab, Autologous stem cell transplant |
| Enrollment | 430 |
| Start date | Oct 1, 1999 |
| Completion | Aug 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 15, 2005 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: